

Remarks/Arguments

Claims 44 - 46, 49 and 57-58 are pending in this application. Claims 52-56, 59 and 60 have been canceled without prejudice to filing a continuation, division or continuation-in-part application directed to the canceled subject matter.

Information Disclosure Statement

Applicants thank the Examiner for consideration of the Information Disclosure Statement filed on June 7, 2005

35 U.S.C. §112, First Paragraph, Rejections

1. Claims 52-56 and 59-60 stand rejected under 35 U.S.C. §112, first paragraph, for lack of enablement allegedly because a polypeptide having at least 80% amino acid sequence identity to the polypeptide of SEQ ID NO:2 which isolated polypeptide inhibits VEGF stimulated proliferation of adrenal cortical capillary endothelial cells, does not reasonably provide enablement for a polypeptide not identical to at least the mature form of SEQ ID NO:2.

Applicants maintain, for the reasons set forth in the previous response that claims 52-56 and 59-60 are fully enabled. However, in the interest of obtaining an allowance, Applicants have deleted claims 52-56 and 59-60 without prejudice to filing a continuation application directed to the canceled subject matter.

Accordingly, this rejection is rendered moot. The Examiner is respectfully requested to withdraw the rejection under 35 U.S.C. 112, first paragraph for lack of enablement.

2. Claims 52-56 and 59-60 stand rejected under 35 U.S.C. §112, first paragraph, for lack of written description.

Applicants maintain, for the reasons set forth in the previous response, that claims 52-56 and 59-60 do not contain subject matter which is not described in the specification. However, in the interest of obtaining an allowance, Applicants have deleted claims 52-56 and 59-60 without prejudice to filing a continuation application directed to the canceled subject matter. Accordingly, this rejection is rendered moot. Withdrawal of this rejection is respectfully requested.

The present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited.

CONCLUSION

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. **08-1641** (Attorney's Docket No. **39780-1618 P2C5**). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Date: October 21, 2005

By: Leslie Mooi
Leslie A. Mooi (Reg. No. 37,047)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025
Direct Dial: (650) 324-6786
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2162243 v1
10/21/05 11:31 AM(39780.1618)